Myovant Sciences is dedicated to addressing unmet needs in women's health through the development and commercialization of innovative therapies. This segment focuses on conditions such as heavy menstrual bleeding associated with uterine fibroids and endometriosis-associated pain. The company's lead product, relugolix, plays a crucial role in this area, offering a once-daily oral treatment option. Research and development efforts are geared towards expanding the applications of relugolix and exploring new therapeutic targets. The company's commitment extends to improving the quality of life for women by providing effective and convenient treatment options, with a focus on patient-centric care and transformative advocacy.

Myovant Sciences is actively involved in the development of therapies for endocrine diseases, with a particular focus on advanced prostate cancer. The company's lead product, relugolix, is utilized in this segment to target gonadotropin-releasing hormone (GnRH) receptors, providing an effective treatment option for patients. Research and development efforts are directed towards exploring new applications of relugolix and identifying novel therapeutic targets within the endocrine system. The company's commitment extends to improving patient outcomes and quality of life through innovative medicines and transformative advocacy, with a focus on addressing unmet needs in endocrine-related conditions.